Tarsons Products growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+7.7%—
EBITDA+6.5%—
Net Income−51.9%—
EPS (adj.)−51.9%—
Total Assets+9.8%+17.8%
Total Equity+0.7%+3.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TARSONS₹304.60

Tarsons Products Limited

· Pharma & Health
₹ CrorePeersFISCHERLAXMIDENTLFABTECHGKBMcap ₹1,621 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+7.7—
EBITDA+6.5—
Net Income-51.9—
EPS (adj.)-51.9—
Total Assets+9.8+17.8
Total Equity+0.7+3.7
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.